Tag: bioCSL global influenza vacine industry
CSL completes acquisition of Novartis flu division
Australian pharmaceutical giant CSL has completed the US $275 million acquisition of Novartis' influenza business.
The transaction will see CSL combine the influenza vaccines division with its...
Featured Article
Good Design Australia opens entries for 2026 awards
For more than six decades, Good Design Australia has celebrated the power of design to shape innovation, industry, and everyday life. Its flagship program, the Australian Good Design Awards, recognises projects that show how thoughtful design can enhance products, services, systems, and communities.
